Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME medical journal. 2020;5.
Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nature Reviews Cardiology. 2016;13(6):368-78.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2021;42(36):3599-726.
Vergaro G, Ghionzoli N, Innocenti L, Taddei C, Giannoni A, Valleggi A, et al. Noncardiac versus cardiac mortality in heart failure with preserved, midrange, and reduced ejection fraction. Journal of the American Heart Association. 2019;8(20):e013441.
Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. Journal of the American College of Cardiology. 2017;70(20):2476-86.
Son MK, Park JJ, Lim N-K, Kim W-H, Choi D-J. Impact of atrial fibrillation in patients with heart failure and reduced, mid-range or preserved ejection fraction. Heart. 2020;106(15):1160-8.
Huusko J, Tuominen S, Studer R, Corda S, Proudfoot C, Lassenius M, et al. Recurrent hospitalizations are associated with increased mortality across the ejection fraction range in heart failure. ESC Heart Failure. 2020;7(5):2406-17.
Farré N, Lupon J, Roig E, Gonzalez-Costello J, Vila J, Perez S, et al. Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain). BMJ open. 2017;7(12):e018719.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Kardiologia Polska (Polish Heart Journal). 2016;74(10):1037-147.
Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. Journal of the American College of Cardiology. 1993;22(4):A6-A13.
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Journal of Echocardiography. 2016;17(12):1321-60.
Nibouche W, Biad A, editors. Hypertension artérielle au moment du diagnostic du diabète de type 2 de l'adulte. Annales de Cardiologie et d'Angéiologie; 2016: Elsevier.
L'ADA E. Diagnostic et classification du diabète sucré les nouveaux critères. Diabetes & Metabolism (Paris). 1999;25:72-83.
Haute Autorité de Santé HAS. Prise en charge de l'hypertension artérielle de l'adulte. Recommandation de bonne pratique. Saint-Denis La Plaine; 2016.
Cheng RK, Cox M, Neely ML, Heidenreich PA, Bhatt DL, Eapen ZJ, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. American heart journal. 2014;168(5):721-30. e3.
Shiga T, Suzuki A, Haruta S, Mori F, Ota Y, Yagi M, et al. Clinical characteristics of hospitalized heart failure patients with preserved, mid‐range, and reduced ejection fractions in Japan. ESC heart failure. 2019;6(3):475-86.
Hamatani Y, Nagai T, Shiraishi Y, Kohsaka S, Nakai M, Nishimura K, et al. Long-term prognostic significance of plasma B-type natriuretic peptide level in patients with acute heart failure with reduced, mid-range, and preserved ejection fractions. The American Journal of Cardiology. 2018;121(6):731-8.
Ito M, Wada H, Sakakura K, Ibe T, Ugata Y, Fujita H, et al. Clinical characteristics and long-term outcomes of patients with acute decompensated heart failure with mid-range ejection fraction. International Heart Journal. 2019;60(4):862-9.
Gottdiener JS, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, et al. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function: the Cardiovascular Health Study. Annals of internal medicine. 2002;137(8):631-9.
Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, et al. Heart failure with mid‐range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME‐CHF). European journal of heart failure. 2017;19(12):1586-96.
Kapłon‐Cieślicka A, Benson L, Chioncel O, Crespo‐Leiro MG, Coats AJ, Anker SD, et al. A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction-insights from the ESC‐HFA EORP Heart Failure Long‐Term Registry. European Journal of Heart Failure. 2022;24(2):335-50.
Farmakis D, Simitsis P, Bistola V, Triposkiadis F, Ikonomidis I, Katsanos S, et al. Acute heart failure with mid-range left ventricular ejection fraction: clinical profile, in-hospital management, and short-term outcome. Clinical Research in Cardiology. 2017;106:359-68.
Yılmaz MB, Çelik A, Çavuşoğlu Y, Bekar L, Onrat E, Eren M, et al. Snapshot evaluation of heart failure in Turkey: Baseline characteristics of SELFIE-TR. Turk Kardiyoloji Dernegi Arsivi. 2019;47(3):198.
Ibrahim NE, Song Y, Cannon CP, Doros G, Russo P, Ponirakis A, et al. Heart failure with mid‐range ejection fraction: characterization of patients from the PINNACLE Registry®. ESC heart failure. 2019;6(4):784-92.
Raja DC, Samarawickrema I, Das S, Mehta A, Tuan L, Jain S, et al. Long‐term mortality in heart failure with mid‐range ejection fraction: systematic review and meta‐analysis. ESC Heart Failure. 2022;9(6):4088-99.
Failure M-aGGiCH. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. European heart journal. 2012;33(14):1750-7.
Lyu S, Yu L, Tan H, Liu S, Liu X, Guo X, et al. Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China. BMC Cardiovascular Disorders. 2019;19(1):1-12.
Özlek B, Özlek E, Çelik O, Çil C, Doğan V, Tekinalp M, et al. Rationale, Design, and Methodology of the APOLLON trial: A comPrehensive, ObservationaL registry of heart faiLure with mid-range and preserved ejectiON fraction. Anatolian journal of cardiology. 2018;19(5):311.
Tsuji K, Sakata Y, Nochioka K, Miura M, Yamauchi T, Onose T, et al. Characterization of heart failure patients with mid‐range left ventricular ejection fraction-a report from the CHART‐2 Study. European journal of heart failure. 2017;19(10):1258-69.
Gomez-Otero I, Ferrero-Gregori A, Román AV, Amigo JS, Pascual-Figal DA, Jiménez JD, et al. Mid-range ejection fraction does not permit risk stratification among patients hospitalized for heart failure. Revista Española de Cardiología (English Edition). 2017;70(5):338-46.
Al-Jarallah M, Rajan R, Al-Zakwani I, Dashti R, Bulbanat B, Ridha M, et al. Mortality and morbidity in HFrEF, HFmrEF, and HFpEF patients with diabetes in the middle east. Oman medical journal. 2020;35(1):e99.
Altaie S, Khalife W. The prognosis of mid‐range ejection fraction heart failure: a systematic review and meta‐analysis. ESC heart failure. 2018;5(6):1008-16.
O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Piña IL, Granger CB, et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007;115(24):3111-20.
Martínez‐Sellés M, Doughty RN, Poppe K, Whalley GA, Earle N, Tribouilloy C, et al. Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta‐analysis. European journal of heart failure. 2012;14(5):473-9.
Bhambhani V, Kizer JR, Lima JA, Van Der Harst P, Bahrami H, Nayor M, et al. Predictors and outcomes of heart failure with mid‐range ejection fraction. European journal of heart failure. 2018;20(4):651-9.
Savarese G, Vasko P, Jonsson Å, Edner M, Dahlström U, Lund LH. The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. Upsala journal of medical sciences. 2019;124(1):65-9.
Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJ, et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. European heart journal. 2018;39(48):4277-84.
Liu D, Hu K, Lau K, Kiwitz T, Robitzkat K, Hammel C, et al. Impact of diastolic dysfunction on outcome in heart failure patients with mid‐range or reduced ejection fraction. ESC Heart Failure. 2021;8(4):2802-15.
Huang T-H, Chiu H, Wu P-Y, Huang J-C, Lin M-Y, Chen S-C, et al. The association of echocardiographic parameters on renal outcomes in chronic kidney disease. Renal Failure. 2021;43(1):433-44.
Takei M, Kohsaka S, Shiraishi Y, Goda A, Nagatomo Y, Mizuno A, et al. Heart failure with midrange ejection fraction in patients admitted for acute decompensation: a report from the Japanese multicenter registry. Journal of Cardiac Failure. 2019;25(8):666-73.
Löfman I, Szummer K, Dahlström U, Jernberg T, Lund LH. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid‐range, and reduced ejection fraction. European journal of heart failure. 2017;19(12):1606-14.
Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. Journal of the American College of Cardiology. 2014;64(21):2281-93.
Group AtCCRiDS, Gerstein H, Miller M, Byington R, Goff Jr D. Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr. Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59.
Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Bmj. 2000;321(7258):405-12.
Lam PH, Packer M, Fonarow GC, Faselis C, Allman RM, Morgan CJ, et al. Early effects of starting doses of enalapril in patients with chronic heart failure in the SOLVD treatment trial. The American Journal of Medicine. 2020;133(2):e25-e31.
Davis BR, Piller LB, Cutler JA, Furberg C, Dunn K, Franklin S, et al. Role of diuretics in the prevention of heart failure: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation. 2006;113(18):2201-10.
Lundbæk K. Diabetic angiopathy: a specific vascular disease. The Lancet. 1954;263(6808):377-9.
Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57:660-71.
Cho JH, Choe W-S, Cho H-J, Lee H-Y, Jang J, Lee SE, et al. Comparison of characteristics and 3-year outcomes in patients with acute heart failure with preserved, mid-range, and reduced ejection fraction. Circulation Journal. 2019;83(2):347-56.
Vedin O, Lam CS, Koh AS, Benson L, Teng THK, Tay WT, et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circulation: heart failure. 2017;10(6):e003875.
Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation. 2018;138(1):80-98.
Savarese G, Jonsson Å, Hallberg A-C, Dahlström U, Edner M, Lund LH. Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum. International journal of cardiology. 2020;298:59-65.
Zhu Y, Peng X, Wu M, Huang H, Li N, Chen Y, et al. Risk factors of short‐term, intermediate‐term, and long‐term cardiac events in patients hospitalized for HFmrEF. ESC Heart Failure. 2022;9(5):3124-38.
Butt JH, Yafasova A, Elming MB, Dixen U, Nielsen JC, Haarbo J, et al. NT-proBNP and ICD in nonischemic systolic heart failure: extended follow-up of the DANISH trial. Heart Failure. 2022;10(3):161-71.
Pufulete M, Maishman R, Dabner L, Higgins JP, Rogers CA, Dayer M, et al. B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data. Systematic reviews. 2018;7:1-21.
Lüers C, Edelmann F, Wachter R, Pieske B, Mende M, Angermann C, et al. Prognostic impact of diastolic dysfunction in systolic heart failure-a cross‐project analysis from the German Competence Network Heart Failure. Clinical cardiology. 2017;40(9):667-73.
Chen J-S, Pei Y, Li C-e, Li N-y, Guo T, Yu J. Prognostic value of heart failure echocardiography index in HF patients with preserved, mid-ranged and reduced ejection fraction. BMC Cardiovascular Disorders. 2020;20:1-6.
Ghio S, Guazzi M, Scardovi AB, Klersy C, Clemenza F, Carluccio E, et al. Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction. European journal of heart failure. 2017;19(7):873-9.
Mostafa S. Assessment of right ventricular systolic function in heart failure with preserved, reduced and mid-range ejection fraction. Indian Heart Journal. 2019;71(5):406-11.
Bytyçi I, Dini FL, Bajraktari A, Pugliese NR, D'Agostino A, Bajraktari G, et al. Speckle tracking-derived left atrial stiffness predicts clinical outcome in heart failure patients with reduced to mid-range ejection fraction. Journal of Clinical Medicine. 2020;9(5):1244.
Guazzi M, Bandera F, Pelissero G, Castelvecchio S, Menicanti L, Ghio S, et al. Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. American Journal of Physiology-Heart and Circulatory Physiology. 2013;305(9):H1373-H81.
Cleland JG, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJ, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European heart journal. 2018;39(1):26-35.
Koh AS, Tay WT, Teng THK, Vedin O, Benson L, Dahlstrom U, et al. A comprehensive population‐based characterization of heart failure with mid‐range ejection fraction. European journal of heart failure. 2017;19(12):1624-34.